Search Within

Christopher G Azzoli

  1. "Maria Arcila"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
Groups
  1. Department of Medicine (5)
  2. Department of Pathology and Laboratory Medicine (5)
  3. Solid Tumor Oncology Division (5)
  4. Thoracic Oncology (4)
  5. GSK Faculty (3)
  6. Human Oncology and Pathogenesis Program (3)

More Groups

People
  1. Maria Arcila (5)
  2. Mark Kris (4)
  3. Vincent Miller (4)
  4. Geoffrey Oxnard (3)
  5. Marc Ladanyi (3)
  6. Gregory Riely (2)

More People

Years
  1. 2014 (1)
  2. 2012 (1)
  3. 2011 (2)
  4. 2010 (1)
Publications
  1. Journal of Thoracic Oncology (2)
  2. Clinical Cancer Research (1)
  3. Clinical Lung Cancer (1)
  4. Journal of Clinical Oncology (1)
Publishers
  1. Elsevier Inc. (3)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation
    Journal Article

    Chaft, J. E.; Litvak, A.; Arcila, M. E.; Patel, P.; D'Angelo, S. P.; Krug, L. M.; Rusch, V.; Mattson, A.; Coeshott, C.; Park, B.; more...
    Clinical Lung Cancer (2014)

    Fulltext@MSK | Save
  • Screening for germline EGFR T790M mutations through lung cancer genotyping
    Journal Article

    Oxnard, G. R.; Miller, V. A.; Robson, M. E.; Azzoli, C. G.; Pao, W.; Ladanyi, M.; Arcila, M. E.
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Meeting Abstract

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; Miller, V. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
    Journal Article

    Price, K. A.; Azzoli, C. G.; Krug, L. M.; Pietanza, M. C.; Rizvi, N. A.; Pao, W.; Kris, M. G.; Riely, G. J.; Heelan, R. T.; Arcila, M. E.; more...
    Journal of Thoracic Oncology (2010)

    Fulltext@MSK | Save